Intermittent Explosive Disorder Clinical Trial
Official title:
An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)
This study is designed to explore the safety and tolerability, and to compare the activity of SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED). Adult Male and Female subjects with a current diagnosis of IED will be enrolled. After a two-week baseline lead-in phase, study subjects who continue to meet enrollment criteria will be randomized to either SRX246 or Placebo treatment groups. Study subjects will be examined and asked to answer questionnaires at weekly scheduled visits throughout the trial. The study results will be determined based on any changes observed over the study period.
This exploratory Phase II study has been designed to examine the safety and tolerability profile, and to compare the activity of the novel V1a vasopressin antagonist (SRX246) against placebo, in adults with DSM-5 Intermittent Explosive Disorder (IED). Adult Male and Female subjects with a current DSM-5 diagnosis of IED will be enrolled. All subjects will undergo systematic diagnostic assessment for DSM-5 Axis I and II disorders. Subjects with DSM-5 IED (without current, co-morbid, DSM-5 Major Depression) whose: (a) Life History of Aggression (LHA) score is > 12, (b) Overt Aggression Scale Modified (OAS-M) "Irritability" score is > 6 and, (c) screening OAS-M "Aggression" score is > 15, will be entered into a two-week baseline lead-in phase. After the lead-in phase, study subjects who continue to meet OAS-M criteria will be randomized to one of the two (2) treatment conditions and stratified by gender so that equal numbers of males and females are assigned to SRX246 and Placebo Groups. Those who do not meet the criteria will exit the protocol at that time. Treatment Conditions: (a) 8-week course of SRX246 (4 weeks at 120 mg bid, and 4 weeks at 160 mg bid) or (b) 8-week course of Placebo, followed by a one-week "taper" to withdraw subjects from study medication. IED subjects in all conditions will have structured diagnostic interview sessions and questionnaires administered throughout the trial. Blinding to treatment condition will be maintained by using different personnel for these activities. Analysis of a change from baseline in the diagnostic measures will be performed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06118567 -
Effect of Nitrous Oxide on Aggression.
|
Phase 2 | |
| Terminated |
NCT00282165 -
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
|
Phase 4 | |
| Not yet recruiting |
NCT04819230 -
A Cognitive Bias Modification RCT for Aggression
|
N/A | |
| Completed |
NCT00078754 -
A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder
|
Phase 2 | |
| Completed |
NCT00399698 -
Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.
|
Phase 3 | |
| Recruiting |
NCT06118580 -
Neural Correlates During Alcohol Intoxication
|
Phase 2 | |
| Completed |
NCT02048241 -
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
|
Phase 4 | |
| Not yet recruiting |
NCT05895513 -
Pimavanserin and Aggression and Social Cognition.
|
Phase 2 | |
| Terminated |
NCT03420222 -
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
|
Phase 2 | |
| Recruiting |
NCT06275607 -
Maladaptive Anger Treatment
|
N/A | |
| Completed |
NCT00127400 -
A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED
|
Phase 2 | |
| Completed |
NCT00667212 -
Psychotherapy for Intermittent Explosive Disorder
|
Phase 2 |